ViroPharma Incorporated (Nasdaq:VPHM) announced that the company's Board of Directors has authorized the use of up to an additional $200 million to repurchase shares of its common stock and/or its 2% Senior Convertible Notes due 2017.

ViroPharma Incorporated, together with its subsidiaries, engages in the development and commercialization of therapeutic products that address serious diseases in the United States and internationally.

Read the full article and disclaimer at: http://pennygovernance.com/?p=16635